The Center for Drug Evaluation (CDE) has released the \u201cTumor Therapeutic Vaccines Clinical Trial Technical Guidelines\u201d (draft proposal), soliciting public feedback until November 8. These guidelines aim to provide a framework for the development and evaluation of tumor therapeutic vaccines, a class of products designed to control and kill tumor cells by inducing or enhancing specific immune responses.<\/p>\n\n\n\n
Tumor Therapeutic Vaccines: Overview<\/strong>
Tumor therapeutic vaccines are designed to control and kill tumor cells, remove small residual lesions, and establish a lasting anti-tumor memory. These vaccines work by inducing or enhancing the specific active immune response of the body against tumor antigens. Multiple technical routes for active immunotherapy exist, with targeted antigens including tumor-specific antigens (TSA), tumor-associated antigens (TAA), or other antigens that contribute to tumor therapy. Depending on the expression and presentation methods of antigens, tumor therapeutic vaccines may include cell vector vaccines, virus vector vaccines, protein\/polypeptide vaccines, nucleic acid (DNA or RNA) vaccines, and others.<\/p>\n\n\n\n